0 Positive results for first Phase III study of long-acting, injectable HIV-treatment regimen
ViiV Healthcare has announced positive 48-week results from its Phase III ATLAS study of a long-acting, injectable, two-drug regimen for treating HIV.
Browsing: Basic > Drug Development
0 Cerebral malaria: attenuating brain injury and mortality with neuregulin-1
Cerebral malaria is the most severe neurological complication of Plasmodium falciparum infection. Here, the authors discuss how NRG-1 could attenuate brain injury and mortality.
0 A peek behind the paper – Jeffrey Henderson on iron in uropathogenic E. coli
In this interview, take a look behind the scenes of a recent Future Microbiology paper on the role of transition metal control in E. coli virulence with author, Jeffrey Henderson.
0 Results from SWORD studies prove the success of a two-drug regimen for HIV
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.
0 US FDA approves first drug for P. vivax treatment in over 50 years
The US FDA have approved Krintafel (tafenoquine) for the radical cure of Plasmodium vivax malaria infections, the first approval for such a drug in 50 years.
0 Novartis drops anti-infectives research
Another big pharmaceutical is retreating from the development of new antibiotics, highlighting concerns around the challenges facing this market.
1 Could bacterial immunotherapy replace antibiotics against Gram-negative bacteria?
Small-molecule compounds designed to tag the cell surface of Gram-negative bacteria and trigger an immunological response have shown promise.
0 Abivax’s Phase II study of HIV drug, ABX464, produces mixed data
In top-line results from a Phase IIa study, Abivax has reported mixed data, although ABX464 did appear to reduce HIV DNA in blood and rectal samples at a higher dose.
0 FDA approves Zemdri for UTIs but not bloodstream infections
The US FDA has approved Zemdri for use in adults with complicated urinary tract infections; however, the agency has also issued a response for bloodstream infections noting there isn’t substantial evidence of Zemdri’s effectiveness.
0 A peek behind the paper – Peter Barlow on antivirals for human rhinovirus infections
Take a look behind the scenes of a recent Future Virology review entitled ‘Antiviral therapeutic approaches for human rhinovirus infections’ as we ask author Peter Barlow about antivirals, antibodies and the host response.
